Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to translating them into tangible clinical evidence and measurable impact.

Good morning, everyone, and thank you so much for joining us. I want to start by briefly framing where Recursion is today and its journey and evolution. Over the past decade, Recursion has built ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...

Rachel Williams has been an editor for nearly two decades. She has spent the last five years working on small business content to help entrepreneurs start and grow their businesses. She’s well-versed ...